GLP-1 drugs linked to lower fracture risk and reduced alcohol cravings

Recent research indicates that GLP-1 receptor agonists, commonly used for weight loss and type 2 diabetes management, may offer unexpected health benefits beyond metabolic control.

A UCLA Health study involving nearly 134,000 Americans aged 50 to 90 found that patients starting GLP-1 treatment had a 21% lower risk of fragility fractures compared to those starting DPP-4 inhibitors. This finding addresses clinical concerns that rapid weight loss might compromise bone density and increase fracture risks in older adults.

Additionally, clinical investigations are exploring the impact of these medications on alcohol consumption. Studies from the University of South Carolina and the University of Colorado Anschutz have observed reductions in heavy drinking days among individuals with alcohol use disorder. Researchers are investigating whether the neural mechanisms regulating satiety and metabolic signaling overlap with the brain's substance reward pathways.